MIRA Pharmaceuticals, Inc. Business Combination, Separately Recognized Transactions, Net Gains and Losses
MIRA Pharmaceuticals, Inc. (MIRA) reported Business Combination, Separately Recognized Transactions, Net Gains and Losses of -$1.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2026-06-30 was -$1.72M.
- MIRA Pharmaceuticals, Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2026-03-31 was -$990.95K.
| Period end | Business Combination, Separately Recognized Transactions, Net Gains and Losses 3 month | Business Combination, Separately Recognized Transactions, Net Gains and Losses 6 month |
|---|---|---|
| 2026-06-30 | -$1.72M 10-Q · filed 2026-08-12 | -$2.71M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$990.95K 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |